Table 2.
Effect of TRPV1 Antagonist on Cardiac Function in Mice (n=6 mice per group)
| Control | Sham | TAC | ||||
|---|---|---|---|---|---|---|
| Vehicle | CPZ (0.1 mg/kg) | CPZ (0.5 mg/kg) | CPZ (2.5 mg/kg) | |||
| HR, bpm in s | 512±38 | 523±65 | 517±63 | 509±45 | 518±38 | 507±32 |
| BW, g | 28.6±3.7 | 27.9±4.3 | 29.8±4.4 | 28.5±3.6 | 28.7±2.9 | 28.3±3.1 |
| HW, mg | 105±15 | 106±13 | 137±19b | 126±21 | 118±16 | 110±14 |
| LW, mg | 171±24 | 173±23 | 192±28 | 181±26 | 183±27 | 185±26 |
| TL, mm | 16.7±4.3 | 17.1±5.4 | 17.1±4.3 | 16.9±4.4 | 17.5±3.6 | 17.2±4.5 |
| HW/TL, mg/mm | 7.6±1.9 | 7.5±2.4 | 9.2±2.6a | 9.0±3.1 | 8.9±2.5 | 8.2±2.2c |
| AW/TL, mg/mm | 0.83±0.06 | 0.82±0.08 | 0.93±0.06a | 0.90±0.05 | 0.88±0.06 | 0.85±0.09c |
| AW/LW, mg/g | 67.4±14.2 | 66.7±15.5 | 93.6±22.5b | 85.6±17.4 | 83.6±16.2c | 76.5±18.5d |
| LVIDd, mm | 3.32±0.36 | 3.42±0.31 | 4.18±0.35b | 3.92±0.68 | 3.61±0.22c | 3.52±0.38c |
| LVIDs, mm | 2.21±0.53 | 2.17±0.32 | 3.34±0.63a | 3.24±0.49 | 2.43±0.31c | 2.37±0.52c |
| EF, % | 65.82±6.37 | 66.84±8.81 | 38.05±10.63b | 39.81±6.77 | 56.83±6.10c | 57.11±6.14c |
| FS, % | 35.58±4.97 | 36.46±6.51 | 18.29±5.34b | 19.57±5.61 | 29.65±3.52d | 30.57±3.41d |
AW indicates atria weight; BW, body weight; CPZ, capsazepine; EF, ejection fraction; FS, fractional shortening; HR, heart rate; HW, heart weight; LVIDd, left ventricular interior end‐diastole dimension; LVIDs, left ventricular interior end‐systole dimension; LW, lung weight; TL, tibia length; TRPV1, transient receptor potential vanilloid type 1.
a
P<0.05.
b
P<0.01 versus sham group.
c
P<0.05.
d
P<0.01 versus transverse aorta constriction vehicle group.